Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
Chung-Wei SuWei TengPo-Ting LinWen-Juei JengKuei-An ChenJason Chia-Hsun HsiehWei-Ting ChenMing-Mo HoChia-Hsun HsiehChing-Ting WangPei-Mei ChaiChen-Chun LinYung-Chang LinShi-Ming LinPublished in: Cancer medicine (2022)
The efficacy and safety of lenvatinib are similar to A + B as a first-line systemic therapy for unresectable HCC.